OneMedNet Partners with Onco-Innovations to Accelerate PNKP Inhibitor Development Using AI-Powered Real-World Data
核心洞察
OneMedNet Corporation (搜索) has entered into a collaboration with Inka Health (搜索), a subsidiary of Onco-Innovations, providing access to its iRWD™ platform powered by Palantir (搜索) Foundry for U.S. real-world oncology data analysis.
The partnership aims to accelerate development of Onco-Innovations' proprietary PNKP Inhibitor Technology (搜索) targeting PTEN/SHP1-deficient cancers (搜索), including patient responder identification and indication expansion beyond advanced metastatic colorectal cancer (搜索).
The collaboration will leverage the iRWD™ platform's ability to identify rare and molecularly defined patient populations at scale, addressing traditional challenges in trial recruitment and evidence development for complex cancer segments.
OneMedNet Corporation (搜索) has announced a strategic collaboration with Inka Health (搜索), a wholly-owned subsidiary of Onco-Innovations Limited (搜索), to accelerate oncology drug development through advanced real-world data analytics and artificial intelligence. The partnership provides Onco-Innovations access to OneMedNet's iRWD™ platform, powered by Palantir (搜索) Foundry, offering comprehensive U.S. real-world oncology data to support the development of innovative cancer treatments.
Targeting Rare Cancer Populations
The collaboration specifically focuses on advancing Onco-Innovations' proprietary PNKP Inhibitor Technology (搜索), which targets PTEN/SHP1-deficient cancers (搜索). Under the agreement, Inka Health (搜索) gains access to OneMedNet's iRWD™ platform through a selective pilot program following technical evaluation and qualification. The partnership aims to accelerate development timelines, reduce clinical and regulatory risk, and strengthen evidence generation for this targeted therapeutic approach.
The collaboration will initially concentrate on applying real-world data and advanced analytics to support the PNKP Inhibitor Technology (搜索)'s development strategy. Key objectives include patient responder identification, indication expansion beyond advanced metastatic colorectal cancer (搜索), and complementary evidence generation to inform clinical and regulatory decision-making.
AI-Enhanced Drug Development Platform
Inka Health (搜索) intends to leverage OneMedNet's iRWD™ platform to improve and further develop SynoGraph™, its causal-inference based AI platform. SynoGraph™ aims to predict the success and safety of potential new cancer treatments by analyzing multimodal medical data, representing a significant advancement in precision oncology development.
The engagement reflects the original architectural intent of the iRWD™ platform: enabling rapid identification and characterization of rare and molecularly defined patient populations at scale. By combining multi-modal data, longitudinal clinical context, and AI-augmented search capabilities, the platform is purpose-built to locate hard-to-find cohorts, such as PTEN (搜索)/SHP1-deficient tumors, and accelerate innovation in areas where traditional trial recruitment and evidence development can be challenging.
Industry Leadership Perspectives
"This collaboration demonstrates exactly what our iRWD™ platform was designed to do—find and characterize rare, high-value patient populations to accelerate innovation," said Aaron Green, CEO & President of OneMedNet. "By bringing together regulatory-grade real-world data, multi-modal clinical depth, and Palantir (搜索)-powered AI, we can help oncology innovators de-risk development, move faster, and generate meaningful evidence in complex disease segments."
Thomas O'Shaunghnessy, CEO of Onco-Innovations, emphasized the critical importance of high-quality data access: "Access to high-quality U.S. oncology real-world data is a critical enabler for PNKP Inhibitor Technology (搜索). This collaboration allows us to better understand real-world patient populations with PTEN (搜索)/SHP1-deficient tumors, identify potential responders, and explore additional indications—helping us de-risk development while improving capital efficiency for shareholders."
Company Background
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission focuses on pursuing the prevention and treatment of cancer through pioneering research and innovative solutions. Onco-Innovations has secured an exclusive worldwide license to patented technology that targets solid tumors (搜索), positioning the company at the forefront of precision oncology development.